Jean Jacques Bienaime, Director at Keros Therapeutics, Inc. (KROS), bought 1,000 shares at $11.70 ($12K) on 2026-04-15, disclosed to the SEC on 2026-04-17.
Scheduled purchase ($12k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| KROS | BUY | 2026-07-17 | $11K | — | Filing → |
| KROS | BUY | 2026-06-17 | $10K | — | Filing → |
| IMNM | BUY | 2026-06-09 | $204K | — | Filing → |